{"id":"atacand-hct-caduet","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hyperkalemia (Atacand/HCT)"},{"rate":null,"effect":"Hypokalemia (Atacand/HCT)"},{"rate":null,"effect":"Muscle pain/myalgia (Caduet)"},{"rate":null,"effect":"Elevated liver enzymes (Caduet)"},{"rate":null,"effect":"Peripheral edema (Caduet)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atacand (candesartan) blocks angiotensin II receptors to relax blood vessels and reduce vasoconstriction, while hydrochlorothiazide promotes sodium and water excretion to decrease blood volume. Caduet combines amlodipine (a dihydropyridine calcium channel blocker that dilates coronary and peripheral vessels) with atorvastatin (a statin that inhibits HMG-CoA reductase to reduce LDL cholesterol synthesis). Together these agents address both hypertension and dyslipidemia.","oneSentence":"Atacand/HCT combines an angiotensin II receptor blocker with a thiazide diuretic to reduce blood pressure through vasodilation and sodium/fluid excretion, while Caduet combines an HMG-CoA reductase inhibitor with a calcium channel blocker to lower cholesterol and blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:54.218Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension (Atacand/HCT)"},{"name":"Hypertension and dyslipidemia (Caduet)"}]},"trialDetails":[{"nctId":"NCT00081731","phase":"PHASE3","title":"Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions","status":"COMPLETED","sponsor":"Baim Institute for Clinical Research","startDate":"2004-04","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypertension, Renovascular","enrollment":947}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Atacand/HCT, Caduet","genericName":"Atacand/HCT, Caduet","companyName":"Baim Institute for Clinical Research","companyId":"baim-institute-for-clinical-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atacand/HCT combines an angiotensin II receptor blocker with a thiazide diuretic to reduce blood pressure through vasodilation and sodium/fluid excretion, while Caduet combines an HMG-CoA reductase inhibitor with a calcium channel blocker to lower cholesterol and blood pressure. Used for Hypertension (Atacand/HCT), Hypertension and dyslipidemia (Caduet).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}